Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone617-431-2313
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees8
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable
Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions
What is Arch Therapeutics' stock symbol?
Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."
How were Arch Therapeutics' earnings last quarter?
Arch Therapeutics Inc (OTCMKTS:ARTH) issued its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.01) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.01). View Arch Therapeutics' Earnings History.
When is Arch Therapeutics' next earnings date?
What price target have analysts set for ARTH?
4 analysts have issued 12-month price objectives for Arch Therapeutics' stock. Their predictions range from $1.25 to $2.50. On average, they anticipate Arch Therapeutics' stock price to reach $1.8750 in the next year. This suggests a possible upside of 569.6% from the stock's current price. View Analyst Price Targets for Arch Therapeutics.
What is the consensus analysts' recommendation for Arch Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arch Therapeutics.
What are Wall Street analysts saying about Arch Therapeutics stock?
Here are some recent quotes from research analysts about Arch Therapeutics stock:
- 1. According to Zacks Investment Research, "Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company's lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. " (8/6/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "We are looking forward to the European agency’s decision, which is expected by this fall. While EU authorities typically render its decision in six months, we believe there is a backlog delaying its decision, driven by recent changes in the governing rules and the impact from Brexit. Arch management has reportedly not heard from the agency and, “…expects the review process to be completed this fall” (10-Q)." (8/5/2019)
- 3. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a risk- adjusted net present value (rNPV) driven by a discounted cash flow (DCF)-based analysis to value Arch Therapeutics shares." (3/18/2019)
Has Arch Therapeutics been receiving favorable news coverage?
News articles about ARTH stock have been trending positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arch Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for Arch Therapeutics.
Who are some of Arch Therapeutics' key competitors?
Some companies that are related to Arch Therapeutics include Neuronetics (STIM), Cytosorbents (CTSO), Repro-Med Systems (REPR), RenovaCare (RCAR), iCAD (ICAD), BRAINSWAY LTD/S (BWAY), Sensus Healthcare (SRTS), Liquidia Technologies (LQDA), Endologix (ELGX), Motus GI (MOTS), Apollo Endosurgery (APEN), Spectral Medical (EDTXF), Pro-Dex (PDEX), AIT Therapeutics (AITB) and BeyondAirInc . (XAIR).
What other stocks do shareholders of Arch Therapeutics own?
Who are Arch Therapeutics' key executives?
Arch Therapeutics' management team includes the folowing people:
- Dr. Terrence W. Norchi, Chairman, Pres, CEO, Sec. & Director (Age 54)
- Mr. Richard E. Davis, CFO & Treasurer (Age 61)
- Dr. Avtar S. Dhillon, Bus. Advisor (Age 57)
- Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific Advisor
- Dr. Steven A. Kates Ph.D., VP of Technology
How do I buy shares of Arch Therapeutics?
Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arch Therapeutics' stock price today?
One share of ARTH stock can currently be purchased for approximately $0.28.
How big of a company is Arch Therapeutics?
What is Arch Therapeutics' official website?
How can I contact Arch Therapeutics?
Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]
MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)
MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
